

## RESULTS OF ANNUAL GENERAL MEETING

**Melbourne, Australia, 30 November 2021:** BARD1 Life Sciences Limited (ASX:BD1) (**BARD1** or the **Company**) held the 2021 Annual General Meeting (AGM) yesterday, 29 November 2021, at 2.00pm (ADST).

Voting for all resolutions tabled at the AGM was conducted by poll. In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001, details of the resolutions and proxies received for the meeting are set out in the attached proxy summary.

*Authorised by the Company Secretary, Tony Di Pietro.*

- ENDS -

### COMPANY CONTACTS

**Dr Leearne Hinch**  
CEO

E [leearne@bard1.com](mailto:leearne@bard1.com)

M +61 400 414 416

**Dr Geoff Cumming**

Non-executive Chairman

E [geoff.cumming@bard1.com](mailto:geoff.cumming@bard1.com)

M +61 417 203 021

### ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) (**BARD1** or the **Company**) is a leading Australian diagnostics company with an innovative portfolio of diagnostic technologies and products. The Company is focused on developing and commercialising diagnostic solutions for healthcare professionals and patients. BARD1 has commercialised the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Our cancer diagnostic pipeline includes tests in development for ovarian and breast cancers, and research-stage projects for prostate and pancreatic cancers. For more information on BARD1, see [www.bard1.com](http://www.bard1.com) and [www.exo-net.com](http://www.exo-net.com).

### FORWARD LOOKING STATEMENTS

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may', 'should', 'expect', 'anticipate', 'estimate', 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.

**BARD1 LIFE SCIENCES LIMITED**  
**ANNUAL GENERAL MEETING**  
**Monday, 29 November 2021**  
**Results of Meeting**

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Adoption of Remuneration Report	Ordinary	16,330,249 94.84%	503,042 2.92%	387,138 2.24%	480,229	17,847,930 96.81%	588,869 3.19%	480,229	Carried
2 Election of Robert Johnston as NED	Ordinary	17,087,366 97.23%	95,228 0.54%	392,453 2.23%	479,655	18,610,362 99.49%	95,228 0.51%	565,482	Carried
3 Approval of 10% Placement Capacity	Special	16,984,151 96.33%	260,020 1.48%	385,428 2.19%	425,103	18,500,122 98.16%	345,847 1.84%	425,103	Carried
4A Ratify issue of Placement Shares and Options	Ordinary	10,895,924 95.06%	179,803 1.57%	385,428 3.37%	498,649	12,411,895 97.90%	265,630 2.10%	498,649	Carried
4B Ratification of issue of SPP Options	Ordinary	15,487,838 94.97%	429,712 2.64%	390,928 2.39%	473,291	16,890,955 97.04%	515,539 2.96%	473,291	Carried
5 Consolidation of performance shares and issue 1	Ordinary	16,583,416 94.35%	597,424 3.40%	396,258 2.25%	477,604	18,110,217 96.36%	683,251 3.64%	477,604	Carried
6A Issue of Options to Dr Geoffrey Cumming	Ordinary	16,433,552 93.65%	714,306 4.07%	398,663 2.28%	480,768	17,962,758 95.74%	800,133 4.26%	480,768	Carried
6B Issue of Options to Mr Robert Max Johnston	Ordinary	16,459,523 93.73%	710,312 4.05%	390,422 2.22%	494,445	17,980,488 95.76%	796,139 4.24%	494,445	Carried
6C Issue of Options to Mr Philip Powell	Ordinary	16,128,854 93.57%	705,259 4.09%	404,138 2.34%	816,451	17,663,535 95.71%	791,086 4.29%	816,451	Carried
6D Issue of Options to Professor Allan Cripps	Ordinary	16,482,437 93.84%	695,572 3.96%	386,873 2.20%	489,820	17,999,853 95.84%	781,399 4.16%	489,820	Carried

7 Change of Company Name	Special	17,024,791 97.09%	123,516 0.70%	386,873 2.21%	519,522	18,542,207 98.88%	209,343 1.12%	519,522	Carried
8 Ratification of the Auditor - Grant Thornton	Ordinary	17,147,034 97.61%	33,188 0.19%	386,873 2.20%	487,607	18,750,277 99.82%	33,188 0.18%	487,607	Carried

\* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.